FDA Discovers NSAID, Unsafe Appetite Suppressant in Weight Loss Supplement
Weight loss supplement Lipo Escultura has been recalled and further manufacturing discontinued after it was found to contain sibutramine and diclofenac. Both substances were found by FDA tests after a consumer reported illness.
Sibutramine is a controlled substance that can significantly increase blood pressure and heart rate in patients, while diclofenac,a non-steroidal anti-inflammatory (NSAID) drug, may cause an increased risk of heart attack and stroke, as well as internal bleeding, ulceration and fatal perforation of the stomach and intestines. Sibutramine, which was previously approved as an appetite suppressant, was removed from the market due to safety concerns.
Labeling on the Lipo Escultura bottle did not mention the inclusion of either substance. Lipo Escultura was sold nationwide by JAT Productos Naturles Corp. via online sales, through the Lipo Escultura store at 888 Wyckoff Avenue in Brooklyn, NY, and a home office at 1360 Hancock Street also in Brooklyn, NY.
Healthcare professionals and patients who experience adverse effects from this product are encouraged to contact the FDA's MedWatch Safety Information and Adverse Event Reporting Program. This can be done by completing an online form (www.fda.gov/MedWatch/report) or calling (800) 332-1088.